Real-World Health Care Resource Utilization, Adherence, and Persistence Following Subcutaneous IgPro20 Initiation Among US Patients with Chronic Inflammatory Demyelinating Polyneuropathy.

Batyrkhan Kuatov¹, Shicheng Weng², Alphonse Hubsch³, Laurence Undreiner⁴, Aisara Chansakul⁵, Ann Madsen⁵, Elizabeth C Dabrowski⁵

¹CSL Behring, Bern, Switzerland. batyrkhan.kuatov@cslbehring.com.

²CSL Behring, Waltham, USA.

³CSL Behring, Bern, Switzerland.

⁴CSL Behring, Paris, France.

⁵Datavant, Phoenix, AZ, USA.

PubMed DOI

Abstract

INTRODUCTION: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, inflammatory peripheral nervous system disorder. Intravenous immunoglobulin (IVIG) has been the standard maintenance therapy, but since 2018, Immune Globulin Subcutaneous (Human), 20% liquid (IgPro20), a subcutaneous immunoglobulin (SCIG) therapy, has offered an alternative, demonstrating benefit in maintaining CIDP…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.